Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China
"We are pleased that Cevira continues to advance toward market approval in
The Asieris media release states: "APL-1702 is a first-in-class, non-surgical treatment for cervical HSIL with its efficacy proven in an international phase III trial. It heralds a potential paradigm shift in the treatment of precancerous cervical lesions, with the clinical focus moving from excision to long-term disease management. Emphasis lies in optimizing the delicate balance between treatment risks and benefits, striving to minimize or delay invasive procedures while effectively reversing the progression of the disease."
Read Asieris' full media release here: https://asieris.com/asieris-announces-nmpa-acceptance-of-nda-for-apl-1702-a-non-surgical-therapy-for-treating-cervical-hsil/
Note to editors:
All trademarks mentioned in this release are protected by law and are registered trademarks of
This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that
About Cevira®
Cevira® (APL-1702) is a photodynamic drug-device combination product in development. Based on the principles of photodynamic therapy, the Cevira product aims to use a photosensitizer in combination with light activation to produce a therapeutic effect as a non-surgical treatment of high-grade squamous intraepithelial lesions (HSIL) in patients aged 18 years and above, excluding carcinoma in situ.
About
About Asieris
CONTACT:
For further information, please contact:
President and CEO
Email: ds@photocure.com
CFO
Tel: +4745055000
Email: ed@photocure.com
Vice President, Investor Relations
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/photocure-partner-asieris-announces-new-drug-application-acceptance-for-regulatory-review-of-cevira-in-china-302143013.html
![](https://rt.prnewswire.com/rt.gif?NewsItemId=EN12102&Transmission_Id=202405120555PR_NEWS_EURO_ND__EN12102&DateId=20240512)